SLGL Stock Analysis: Buy, Sell, or Hold?
SLGL - Sol-Gel Technologies Ltd. Ordinary Shares
$77.92
-6.82 (-8.05%)
âŧ
5d:
-7.78%
30d:
+5.43%
90d:
+11.35%
WAIT
LOW Confidence
Analysis Updated: Aug 11, 2026 12:00 AM ET
Earnings: Aug 21, 2026
8d
Get Alerted When SLGL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: SLGL is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: SLGL is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: SLGL is currently trading at $77.92, which is considered slightly low relative to its 30-day fair value range of $76.45 to $85.55.
Technical Outlook: Technically, SLGL is in a uptrend. The price is currently testing key support at $77.07. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.0% recently.
Market Sentiment: SLGL scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $193.00 (+127.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SLGL is in a uptrend. The price is currently testing key support at $77.07. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.0% recently.
Market Sentiment: SLGL scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $193.00 (+127.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$76.45 -
$85.55
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (38/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.0%)
- BULLISH: Trading 127.8% below Wall St target ($193.00)
- WARNING: Composite score 47/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$76.45 -
$85.55
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$77.07
Resistance Level
$90.72
Current Trend
Uptrend
Technical data as of
Aug 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-10.40
Wall Street Target
$193.00
(+127.8%)
Revenue Growth (YoY)
-89.5%
Earnings Growth (YoY)
487.6%
Profit Margin
-5.7%
Share & Embed Analysis
Last updated: August 12, 2026 5:00 AM ET
Data refreshes hourly during market hours. Next update: 6:00 AM
Data refreshes hourly during market hours. Next update: 6:00 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SLGL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 65 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 61 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 65 BUY |
|
RCKT
Rocket Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$9 | 46 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$52 | 62 BUY |
